Quality of life measures

Quality of Life Measures in Clinical Trials

Quality of Life (QoL) measures evaluate the impact of a medical condition or treatment on a patient’s overall well-being, beyond traditional clinical endpoints such as survival or symptom control. These measures are essential in trials where patient-centered outcomes are critical, especially in chronic illness, cancer, mental health, and palliative care.

What is Quality of Life?

QoL refers to a multidimensional concept that includes:

• Physical well-being (e.g., fatigue, pain)
• Psychological health (e.g., anxiety, depression)
• Social functioning (e.g., relationships, support)
• Functional status (e.g., ability to perform daily tasks)

When measured in health research, it’s often referred to as Health-Related Quality of Life (HRQoL).

Why Include QoL Measures in Clinical Trials?

There are several important reasons to include Quality of Life (QoL) measures in clinical trials. First, they allow for a more holistic evaluation of treatment by capturing the impact beyond biological or clinical markers, such as how a patient feels or functions in daily life. Second, they promote patient-centered research, ensuring that outcomes reflect what matters most to patients—not just clinicians or researchers.

QoL measures also enhance benefit-risk assessment by helping weigh adverse effects against perceived benefits from the patient's perspective. In addition, they inform decision-making, supporting shared choices between patients and healthcare providers based on real-world impacts. Finally, QoL data are increasingly used to support regulatory and reimbursement decisions, as agencies and payers look beyond clinical efficacy to consider the broader value of interventions.

Commonly Used QoL Instruments

Generic Instruments (Applicable across a wide range of conditions):

• SF-36 / SF-12: Short Form Health Survey
• EQ-5D: EuroQol five-dimension scale
• WHOQOL: World Health Organization Quality of Life instruments

Disease-Specific Instruments (Tailored to specific conditions):

• EORTC QLQ-C30 (for cancer)
• FACT-G (Functional Assessment of Cancer Therapy – General)
• AQLQ (Asthma Quality of Life Questionnaire)
• MSQoL-54 (Multiple Sclerosis QoL)

Design Considerations When Using QoL Measures

Several key design considerations must be addressed when incorporating Quality of Life (QoL) measures in clinical trials. First, careful instrument selection is essential. Researchers should ensure the tool is validated for the target population and language, and that it accurately captures the relevant domains of QoL for the condition under study.

Next, the timing of measurement must be strategically planned. QoL should be assessed at baseline, during follow-up, and ideally over the long term to capture changes over time. The timing should align with the expected trajectory of effects and the duration of the trial.

The mode of administration also affects data quality. QoL data may be collected via paper-based forms, electronic systems (ePRO), or interviews, but regardless of method, accessibility and consistency must be prioritized.

Because missing data is common in QoL assessments, proper planning for handling missing data is crucial. Investigators should use appropriate imputation methods and conduct sensitivity analyses to assess the robustness of findings.

Finally, statistical analysis of QoL data requires specific techniques. Researchers may use summary scores, responder definitions, or area-under-the-curve (AUC) approaches. It’s important to adjust for baseline QoL values and address potential skewness in the data to ensure valid and interpretable results.

Interpreting QoL Outcomes

• Clinically meaningful difference (e.g., Minimal Important Difference or MID) is key for interpretation
• Effects should be reported with confidence intervals, and visualized where possible (e.g., line graphs over time)
• Researchers should distinguish between statistical significance and clinical relevance

Regulatory and Reporting Guidelines

• Follow SPIRIT-PRO (for protocol design) and CONSORT-PRO (for reporting) when QoL is a primary or secondary outcome
• Register QoL measures in advance on platforms like ClinicalTrials.gov or other trial registries

Conclusion

Incorporating quality of life measures in clinical trials ensures that research reflects the lived experiences of participants. By capturing how treatments affect physical, emotional, and social well-being, QoL data adds depth, meaning, and relevance to clinical evidence.

---

Bibliography

1. Aaronson NK, Ahmedzai S, Bergman B, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. Journal of the National Cancer Institute. 1993;85(5):365–376.
2. Cella DF, Tulsky DS, Gray G, et al. The Functional Assessment of Cancer Therapy (FACT) scale: development and validation of the general measure. Journal of Clinical Oncology. 1993;11(3):570–579.
3. Revicki DA, Osoba D, Fairclough D, et al. Recommendations on health-related quality of life research to support labeling and promotional claims in the United States. Quality of Life Research. 2000;9(8):887–900.
4. Ware JE, Sherbourne CD. The MOS 36-item short-form health survey (SF-36): I. Conceptual framework and item selection. Medical Care. 1992;30(6):473–483.
5. Calvert M, Blazeby J, Revicki D, et al. Reporting of patient-reported outcomes in randomized trials: the CONSORT PRO extension. JAMA. 2013;309(8):814–822.

---

Adapted for educational use. Please cite relevant trial methodology sources when using this material in research or teaching.